Back to News
Market Impact: 0.25
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
Source: Nasdaq
Healthcare & Biotech
CSL and Alentis Therapeutics entered an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class claudin-1-targeting therapy for rare kidney, liver and other diseases. The provided article text gives no financial terms, development milestones or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- Vaxcyte shares surge on late-stage vaccine trial success